The drug was a costume, worn once and set aside after the ceremony.
In a New Delhi clinic's social media feed, the pitch is direct: guided nutrition, Mounjaro injections, and smart workouts — all packaged under the banner of becoming a 'Mounjaro bride.' It is a telling phrase, and it points toward something larger happening across India's booming wellness industry, where weight-loss drugs originally designed for diabetics and the clinically obese are finding a new and eager market: people counting down to their wedding day.
Klarity Skin Clinic in New Delhi is among the more explicit operators, branding its offering around the drug by name. Other clinics have been quieter about it, folding injectable weight-loss treatments into broader pre-wedding packages that traditionally centered on facials, skin brightening, and hair treatments. The clinic did not respond to requests for comment, but the trend it represents is visible enough that eight doctors interviewed by Reuters all said they had been fielding inquiries from brides — and some grooms — specifically asking about these medications before their ceremonies.
The drug most in demand is Eli Lilly's Mounjaro, a GLP-1 receptor agonist that entered India's market for both diabetes and weight management and has since outpaced Novo Nordisk's Wegovy in sales. Mounjaro sales doubled in the months following its launch, making it the top-selling drug of its kind in the world's most populous country. The lowest monthly dose runs about 13,125 rupees — roughly $140 — while the highest costs nearly 26,000 rupees. Novo, which recently cut prices on its competing products for the second time, now sells its lowest Wegovy dose for around 5,660 rupees a month.
Rajat Goel, a bariatric surgeon at Hindivine Healthcare in New Delhi, said that over the past several months, more than 20 percent of his clinic's inquiries about obesity injections have come from women preparing for marriage — many of whom volunteer exactly how many weeks remain before the ceremony. He said he prescribes the drugs only when patients meet medical criteria, not for cosmetic purposes alone.
The women who spoke to Reuters about their experiences were candid about the pressures driving them. Aditi, a 26-year-old finance worker from Mumbai, started Mounjaro in November after diet and exercise hadn't delivered the results she wanted. She lost 10 kilograms before her February wedding. 'If I am not happy, I don't feel confident,' she said. 'I did not want to feel that way at the time of the wedding.' Akshitha, who married in Hyderabad last year, shed 15 kilograms with the help of the injections, dropping to 76 kilograms before her ceremony. She had been pointed toward the drugs by a family doctor when she expressed concern about her weight, and she noted that the chaos of wedding planning made gym time and strict dieting feel impossible.
For Priya, a 27-year-old tech worker from Bengaluru, the stakes were higher and the wound more specific. Prospective grooms and their families had rejected her because of her weight — she was told plainly that she was too fat. She began with an oral semaglutide approved in India for diabetes, using it off-label, and lost more than 12 kilograms before switching to injectable Mounjaro. She is still looking for a husband.
India's wedding culture carries enormous weight — literally and figuratively. Many marriages remain family-arranged affairs, with appearance and financial standing scrutinized by both sides. The pressure to present a particular body at the ceremony is not new; what is new is the pharmaceutical shortcut now available to address it. Most of the brides and the one groom who spoke to Reuters said they had stopped the injections shortly after the wedding.
The drugs are approved for adults who are clinically obese or overweight with related conditions such as diabetes, hypertension, or sleep apnea. Eli Lilly has stated that Mounjaro is intended only for specific medical indications and must be used under professional supervision. Novo Nordisk has said it discourages self-medication or any deviation from labeled use. India's drug regulator has grown concerned enough about misuse that it has intensified scrutiny of unauthorized sales and promotion, particularly as domestic manufacturers have begun flooding the market with cheaper versions of semaglutide following the expiration of Novo's patent.
Dr. Swati Pradhan, who runs an obesity and metabolic wellness clinic called Live Light, said she prescribes the injections to a small number of pre-wedding patients only when they meet medical criteria and show signs of other health issues — and only alongside a commitment to lasting lifestyle changes. 'We understand the curiosity,' she said, 'but this cannot be a quick fix.' India's weight-loss drug market is projected to reach 80 billion rupees by 2030, and with more than 440 million people forecast to be overweight or obese by 2050, the pressure on regulators to draw clear lines between treatment and trend is only going to intensify.
Notable Quotes
Over 20% of the queries we've received for obesity injections are from to-be brides, who also openly give us a timeline on how soon they are getting married.— Rajat Goel, bariatric surgeon, Hindivine Healthcare, New Delhi
I've had men and their families reject my proposal because of my weight. I was told I was fat.— Priya, 27-year-old tech worker from Bengaluru
The Hearth Conversation Another angle on the story
What's actually driving this — is it vanity, or something more structural?
It's both, and they're hard to separate. The wedding in India isn't just a personal milestone. It's a public performance evaluated by two families, sometimes hundreds of guests. Appearance is part of the audition.
Priya's story hit differently. She wasn't just preparing for a wedding — she was trying to survive a selection process.
Right. She wasn't optimizing for a photo. She was responding to explicit rejection. That's a different kind of pressure, and it says something about what these drugs are being asked to solve.
The doctors seem to be threading a needle — prescribing only when medically justified, but the demand is clearly cosmetic.
That tension is real. When 20 percent of your inquiries come from brides citing a wedding date as their timeline, the clinical framing starts to feel strained.
Most of the women stopped the injections after the wedding. What does that tell us?
That the goal was never long-term health management. It was a specific event, a specific image. The drug was a costume, in a way.
Is the cheaper generic market going to make this worse?
Almost certainly. When the price drops low enough, the medical gatekeeping becomes the only barrier — and that barrier is already porous.
The regulator is watching. Does that matter?
It matters at the margins. But when social pressure is this intense and the drugs are this accessible, regulation tends to chase the problem rather than contain it.